SUSQUEHANNA INTERNATIONAL GROUP, LLP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 113 filers reported holding THERAVANCE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is 1.00 and the average weighting 0.2%.

Quarter-by-quarter ownership
SUSQUEHANNA INTERNATIONAL GROUP, LLP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$1,081,995
+55.5%
125,376
+86.5%
0.00%
Q2 2023$695,831
-69.4%
67,230
-67.9%
0.00%
Q1 2023$2,272,121
-52.7%
209,412
-51.1%
0.00%
-100.0%
Q4 2022$4,805,728
+32.9%
428,318
+20.2%
0.00%
Q3 2022$3,615,000
+81.8%
356,482
+62.5%
0.00%
Q2 2022$1,988,000
-16.9%
219,418
-12.3%
0.00%
Q1 2022$2,392,000
-61.5%
250,179
-55.6%
0.00%
Q4 2021$6,220,000
+53.0%
562,922
+2.5%
0.00%
Q3 2021$4,066,000
+344.4%
549,419
+772.1%
0.00%
Q2 2021$915,000
-50.3%
63,000
-30.2%
0.00%
Q1 2021$1,841,000
+367.3%
90,200
+307.0%
0.00%
Q4 2020$394,000
-74.0%
22,162
-78.4%
0.00%
Q3 2020$1,518,000
+33.7%
102,706
+89.9%
0.00%
Q2 2020$1,135,000
-14.9%
54,087
-6.3%
0.00%
Q1 2020$1,334,000
+84.8%
57,702
+55.7%
0.00%
Q3 2019$722,000
-82.9%
37,065
-85.7%
0.00%
Q2 2019$4,234,000
+481.6%
259,205
+707.5%
0.00%
Q1 2019$728,000
+50.4%
32,100
+69.6%
0.00%
Q4 2018$484,000
+28.7%
18,924
+64.6%
0.00%
Q3 2018$376,000
-73.3%
11,500
-77.2%
0.00%
Q4 2017$1,407,000
+93.0%
50,459
+136.9%
0.00%
Q3 2017$729,000
+4.1%
21,300
+21.3%
0.00%
Q2 2017$700,000
-32.6%
17,564
-37.7%
0.00%
Q1 2017$1,038,000
-64.4%
28,200
-69.1%
0.00%
-100.0%
Q4 2016$2,912,000
+727.3%
91,317
+841.4%
0.00%
Q3 2016$352,000
+55.8%
9,700
-52.8%
0.00%
Q3 2015$226,000
-35.4%
20,563
-23.3%
0.00%
Q2 2015$350,000
-47.3%
26,813
-39.8%
0.00%
Q4 2014$664,000
+26.7%
44,531
+171.1%
0.00%
Q2 2014$524,00016,4280.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders